Sedat CANER, Akif ALTINBAŞ, Yusuf YEŞİL, Yavuz BEYAZIT, Barış YILMAZ, Osman YÜKSEL

The relation between Helicobacter pylori and ulcerative colitis

Besides some genetic explanations of the native course of ulcerative colitis (UC), the most attributable factors are pathogenic bacterial agents. There are some conflicting data about the relationship between Helicobacter pylori and the rate of UC in the literature. Therefore, we aimed to investigate the rate of H. pylori in UC patients. Materials and methods: Forty-nine individuals diagnosed with UC who had undergone upper gastrointestinal tract endoscopy for different reasons were included in the study. The presence of H. pylori in the stomach was checked by histopathological examination. Results: H. pylori positivity was present in 57.1% of patients with UC. Interestingly, H. pylori positivity was lower (11.1%) in pancolitis patients compared to those presenting with more limited illnesses. There were no relationships among the severity of the underlying disease, medication already used, and H. pylori positivity rate. Conclusion: The extension of UC is important for the positivity rate of H. pylori. It could not be determined whether the low positivity of H. pylori in extended UC cases was due to immunosuppressive drugs or to the UC itself.

Anahtar Kelimeler:

Ulcerative colitis, Helicobacter pylori, immunosuppressive drugs

The relation between Helicobacter pylori and ulcerative colitis

Keywords:

Ulcerative colitis, Helicobacter pylori, immunosuppressive drugs,

PDF

___

1. Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 2012;160: 29–44.
2. Altınbas A, Koybasıoglu F, Aktas E, Yılmaz B, Coban S. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C. Inflamm Bowel Dis 2011;17: 1050.
3. Louis E, Van Kemseke C, Latour P, Belaiche J, Reenaers C. Genetics and environment in chronic inflammatory bowel diseases. Rev Med Liege 2012; 67: 298–304 (article in French with English abstract).
4. Dogruman-Al F, Simsek Z, Boorom K, Ekici E, Sahin M, Tuncer C, Kustimur S, Altinbas A. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey. PLoS One 2010; 5: e15484.
5. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40: 619–626.
6. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol 2012; 47: 609–618.
7. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 (Suppl. 1): 60–68.
8. Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol 2012; 24: 429–434.
9. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, McColl KE. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994; 35: 1385–1388.
10. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 439–443.
11. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol 2003; 36: 22–25.
12. Triantafillidis JK, Gikas A, Apostolidiss N, Merikas E, Mallass E, Peros G. The low prevalence of Helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol 2003; 98: 1213–1214.
13. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–1181.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041–1048.
15. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 2003; 61: 105–110.
16. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, Lamers CB, van Hogezand RA. Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn’s disease. Scand J Gastroenterol 1997; 32: 712–718.
17. Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, Rembacken B, Axon AT, Bianchi Porro G. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A crosssectional study with matching. Scand J Gastroenterol 1997; 32: 1140–1146.
18. Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol 1984; 33: 407–412.
19. Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1732–1735.
20. Halme L, Rautelin H, Leidenius M, Kosunen TU. Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease. J Clin Pathol 1996; 49: 65–67.